Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

TRPC6 governs brown adipose thermogenesis via a BMPR2-p38 MAPK signaling axis

Xie D., Peng Y., Zhang S., Mai X., Wen W., Wang M.

Animal Study on Type 2 Diabetes, published in Mol Metab (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Metab (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41747880
PMCID
PMC12969644
DOI
10.1016/j.molmet.2026.102341
Citations
1

Abstract (original English)

Brown adipose tissue (BAT) thermogenesis combats obesity, but mechanisms linking calcium dynamics to thermogenic programming remain incompletely defined. Here, we identify the calcium channel TRPC6 as an essential BAT-intrinsic regulator of metabolic health. BAT-specific Trpc6 knockout (Trpc6 BTKO ) mice exhibit spontaneous BAT whitening, mitochondrial dysfunction, and impaired cold tolerance. Upon high-fat diet (HFD) challenge, Trpc6 BTKO mice develop exacerbated obesity, hepatic steatosis, and insulin resistance. These phenotypes are driven by increased energy intake and reduced energy expenditure associated with impaired thermogenesis. TRPC6 deficiency suppresses mitochondrial biogenesis and thermogenesis. Mechanistically, TRPC6 mediates calcium influx and interacts directly with BMPR2, thereby selectively activating p38 MAPK signaling to drive thermogenic gene expression. Genetic disruption of the TRPC6-BMPR2 complex abolishes TRPC6-mediated thermogenesis. Thus, we define a non-redundant TRPC6-BMPR2-p38 MAPK signaling axis whose disruption underpins obesity and associated metabolic dysfunction, positioning it as a promising therapeutic target for metabolic disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MitochondriaAnimalsMice, Inbred C57BLMice, KnockoutHumansMiceObesityp38 Mitogen-Activated Protein KinasesSignal TransductionMAP Kinase Signaling System

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research